Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
J Pediatr Hematol Oncol ; 46(6): 311-318, 2024 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-38884491

RESUMEN

BACKGROUND: Detection of cancer predisposition syndromes (CPS) depends on identifying risk factors, including tumor type, family history, and physical findings, to prompt referral for genetic counseling/testing. Whether pediatric oncology providers (POPs) collect adequate family history information is unknown. METHODS: A single-institution retrospective chart review of solid tumor patients <18 years of age referred for a CPS evaluation between January 1, 2017 and January 31, 2019 was performed. POP adherence to American Society of Clinical Oncology (ASCO) family history collection recommendations was measured and compared with genetic counselor performance. Whether sufficient family history was documented to satisfy the criteria of three genetic counseling referral guidelines [American College of Medical Genetics (ACMG), updated Jongmans (UJ), and McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG)] was evaluated. RESULTS: POPs and genetic counselors achieved all 6 ASCO family history metrics in 3% and 99% of 129 eligible cases, respectively. POPs failed to document sufficient family history to satisfy genetic counseling referral criteria in most cases (74% ACMG, 73% UJ, 79% MIPOGG). CONCLUSIONS: POPs perform poorly in family history collection, raising concern that some patients at risk for a CPS based on their family history may not be referred for genetic counseling/testing. Interventions to improve family history collection are needed to enhance CPS detection.


Asunto(s)
Asesoramiento Genético , Predisposición Genética a la Enfermedad , Neoplasias , Humanos , Estudios Retrospectivos , Niño , Femenino , Masculino , Adolescente , Neoplasias/genética , Neoplasias/diagnóstico , Preescolar , Pruebas Genéticas/métodos , Lactante , Síndromes Neoplásicos Hereditarios/diagnóstico , Síndromes Neoplásicos Hereditarios/genética , Anamnesis
2.
J Pediatr Hematol Oncol ; 46(5): e334-e337, 2024 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-38691023

RESUMEN

High-grade endometrial stromal sarcoma is a rare and aggressive soft tissue tumor characterized by YWHAE::NUTM2A/B translocations, diagnosis at a median of 50-60 years, and a poor prognosis (overall survival 30%-40%). We describe a 16-year-old patient with high-grade endometrial stromal sarcoma and regional nodal and pulmonary metastases who is a long-term survivor after grossly complete tumor resection, intensive chemotherapy, and pelvic radiotherapy. We discovered a previously undescribed YWHAE::NUTM2E translocation in the tumor. Our patient's favorable outcome suggests that intensive multimodality therapy with curative intent is appropriate for young patients with high-grade endometrial stromal sarcoma and highlights the importance of fertility preservation.


Asunto(s)
Neoplasias Endometriales , Sarcoma Estromático Endometrial , Humanos , Femenino , Adolescente , Sarcoma Estromático Endometrial/patología , Sarcoma Estromático Endometrial/terapia , Neoplasias Endometriales/patología , Neoplasias Endometriales/terapia , Translocación Genética , Terapia Combinada , Pronóstico , Preservación de la Fertilidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA